Oral @entity927 with XXXX -Based Triple Combination Cream Versus @entity21289 -Based Triple Combination Cream Alone in Melasma: An Open Labeled Randomized Comparative Trial.

@entity1 @entity21289 @entity20773 @entity8156 @entity2117 @entity1709 @entity1351 @entity927 @entity1968
BACKGROUND: Melasma is a common acquired cause of @entity2117 with no definitive therapy. @entity927 , a @entity1351 inhibitor, has demonstrated depigmenting properties and combining this oral drug with other modalities of treatment has shown promising results. OBJECTIVES: To compare the efficacy of a combination of oral @entity927 and @entity21289 -based triple combination cream with that of @entity21289 -based triple combination cream alone in @entity1709 among Indian @entity1 . MATERIALS AND METHODS: 40 @entity1 of @entity1709 of either sex attending to dermatology OPD were enrolled in this study. @entity1 were randomly divided into two groups with 20 @entity1 in each group. Group A @entity1 were asked to apply the cream only and Group B @entity1 received oral @entity927 250 mg twice daily and applied a triple combination cream containing @entity20773 0.01%, @entity1968 0.05%, and @entity8156 2% once daily for 8 weeks. Response was evaluated using @entity1709 area severity index (MASI) at baseline, 4 weeks, and 8 weeks. RESULTS: 40 @entity1 completed the study. The MASI scores at baseline, 4 weeks and 8 weeks in group A were 15.425 + 1.09, 11.075 + 9.167 and 6.995 + 6.056 respectively and in group B 18.243 + 1.05, 6.135 + 4.94 and 2.19 + 3.38. Intergroup comparison showed a faster reduction in pigmentation in Group B as compared to Group A and the results were statistically significant at 4 weeks (P value 0.014) and 8 weeks (P value 0.000). The efficacy was maintained throughout the 6-month follow-up period. CONCLUSION: Addition of oral @entity927 to @entity21289 -based triple combination cream results in a faster and sustained improvement in the treatment of @entity1709 .
